Quoin Pharmaceuticals Announces Publication of Peer-Reviewed Paper on QRX003 for Netherton Syndrome in Dermatology and Therapy

One child’s severe skin symptoms became mostly clear during 21 months on an experimental lotion.

Quoin Pharma Announces Publication Of Peer-Reviewed Paper Introducing QRX003 And Its Mechanism Of Action In Netherton Syndrome

Canaccord Genuity Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $18

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Europe gives a rare skin disease drug special status. Approval could bring 10 years' exclusivity.

Quoin Pharmaceuticals’ Lead Product Candidate QRX003 Granted Orphan Drug Designation By European Medicines Agency For Treatment Of Peeling Skin Syndrome

This Robinhood Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

BTIG Initiates Coverage On Quoin Pharmaceuticals with Buy Rating, Announces Price Target of $14

12 Health Care Stocks Moving In Wednesday's After-Market Session

Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy

Quoin Pharmaceuticals Announces Publication Acceptance Of QRX003 Netherton Syndrome Manuscript Featuring Pediatric Compassionate-Use Case Report In Dermatology and Therapy Issue

Quoin Pharmaceuticals Announces FDA Fast Track Designation for QRX003 for the Treatment of Peeling Skin Syndrome

Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU

CORRECTION -- Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Peeling Skin Syndrome